AMRA Announces $9 Million Investment from Pfizer Venture Investments, Novo Seeds and Industrifonden

Uncategorized January 17, 2017 at 4:24 PM 0 comments

AMRA is the leader in setting the new standard for advanced body composition measurement Investment supports AMRA’s goal to redefine obesity and support clinical trials Sweden, January 17, 2017 – Swedish-based digital health company AMRA has announced today a $9 million funding round co-led by US-based Pfizer Venture Investments and leadingRead More

Introducing EMJ Innovations 1.1

Introducing EMJ Innovations 1.1

Innovations January 10, 2017 at 9:01 AM 0 comments

United Kingdom, January 10, 2017: Happy new year and welcome to our first journal of the year, the inaugural edition of the European Medical Journal Innovations eJournal, our new venture aimed at presenting recent developments in medical modernisation and eagerly anticipated technological advances of the near future. With highlights fromRead More

RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT® for Migraines with Pharmatronic Co. In South Korea

Oncology December 19, 2016 at 9:41 AM 0 comments

RedHill and its co-development partner, IntelGenxCorp. (IntelGenx), have signed a definitive agreement with Pharmatronic Co., granting an exclusive license to commercialize the acute migraine drug RIZAPORT® in South Korea This agreement follows the previously announced commercialization agreement with Grupo JUSTE S.A.Q.F for Spain, and the subsequent submission of a nationalRead More

Bluebird Bio and Apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement

Oncology December 19, 2016 at 9:35 AM 0 comments

USA and Germany, December 15, 2016 – bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer and apceth Biopharma GmbH (, the global innovator and leader in the development of engineered mesenchymal stem cell (MSC)Read More

First Data on Rare Sarcomas in Asian Patients Presented at ESMO Asia in Singapore

Oncology December 19, 2016 at 9:29 AM 0 comments

Research to be presented at the ESMO Asia 2016 Congress. Lugano-Singapore, December  17, 2016 – The first data on rare sarcomas in Asian patients is presented in three studies today at the ESMO Asia 2016 Congress in Singapore. Just half of patients with advanced angiosarcoma received chemotherapy even though itRead More

RedHill Biopharma Announces Positive and Unanimous DSMB Recommendation for Continuation of Phase III Study with RHB-104 for Crohn’s Disease

Gastroenterology December 16, 2016 at 9:26 AM 0 comments

Following a pre-planned review of safety data, RedHill has received a unanimous recommendation from the independent Data and Safety Monitoring Board (DSMB) to continue the MAP US Phase III study with RHB-104 for Crohn’s disease as planned, without any modifications A second DSMB meeting, expected in Q2/2017, will include anRead More

Three New Studies Presented at San Antonio Breast Cancer Symposium Further Demonstrate Value of MammaPrint® and BluePrint® in Individualizing Treatment for Breast Cancer Patients

Oncology December 16, 2016 at 9:15 AM 0 comments

Long-term follow-up of early-stage breast cancer patients shows significant difference in how gene expression-based tests classify patients for adjuvant chemotherapy treatment, finds MammaPrint® the best predictor of distant cancer recurrence MINT trial confirms stratification of patients classified by MammaPrint as High Risk into two sub-categories to help predict benefit ofRead More

Almost 20% of Breast Cancer Patients Fail to Complete Prescribed Endocrine Therapy

Oncology December 14, 2016 at 4:05 PM 0 comments

Research to be presented at the ESMO Asia 2016 Congress Lugano-Singapore, December 14, 2016 – Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore.1 The study in over 5,500 women found that younger patients and those whoRead More

LifeCodexx Receives CE Mark for its Novel NIPT Solution Based On Methylation-Specific Quantitative PCR

Reproductive Health December 13, 2016 at 2:12 PM 0 comments

The proprietary qNIPT technology to become a cost efficient and rapid NIPT Germany, December 07, 2016 – LifeCodexx AG, Europe’s first NIPT provider, announced today CE marking of its PrenaTest® BioIT analysis software based on an innovative methylation-specific qPCR assay for the detection of fetal trisomy 21 (qNIPT). Now the proprietaryRead More

Introducing the European Medical Journal 1.4

Introducing the European Medical Journal 1.4

Uncategorized December 13, 2016 at 9:38 AM 0 comments

United Kingdom, December 13, 2016: Greetings and welcome to the final journal for this year, the flagship European Medical Journal, a compendium of multidisciplinary modernisation and evolution drawn from across numerous therapeutic areas; the ideal publication to draw this eventful year to a close and entice your anticipation for 2017.Read More